Chief medical informatics officer

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, Ayala, LLM, OTCQX, CPA, Plantar fibromatosis, Doctor of Philosophy, MBA, Master of Science, CFO, Chief medical informatics officer, FACP, Berlin, AML, Pharmaceutical industry, Management, MD

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.

Key Points: 
  • REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.
  • The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”).
  • “We are pleased to close the merger with Biosight which expands our product pipeline,” said Ken Berlin, President & CEO.
  • Roy Golan, CPA, LLM, previously Executive VP & CFO of Biosight, has been appointed Chief Financial Officer of the combined company.

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

Retrieved on: 
Thursday, October 19, 2023
AEX, Sustainability, NYSE, PHG, Philips, Carbon, Health, Helium, Environment, COCIR, Tampere University, Design, Hospital, Dragon's Heart Hospital, CFO, Part, Champalimaud Foundation, Chief medical informatics officer, Patient, Google Images, Ingenia, Vanderbilt University Medical Center, Medical imaging, Nursing, Television

“Sustainability is an integral part of Tampere Heart Hospital strategy.

Key Points: 
  • “Sustainability is an integral part of Tampere Heart Hospital strategy.
  • We are aware that hospitals generate a significant amount of waste daily and consume a lot of energy.
  • We want to contribute to the development of environmental responsibility in healthcare,” said Pasi Lehto CEO and Chief Medical Officer at Heart Hospital.
  • “We want to ascertain where we are now and how we can further accelerate our transition towards net zero,” said Aki Haukilahti, CFO at Tampere Heart Hospital.

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition

Retrieved on: 
Wednesday, October 25, 2023
Takeda Pharmaceutical Company, Gastroenterology, Clinical Science (journal), Faculty, Research, CGMP, IND, Biogen, Hepatitis C, CMC, Conditional sentence, Liver, Fibrosis, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, IPF, Gilead Sciences, McGill University, PSC, Death, Lung, NASH, KOL, Antibody, Partnership, Internal medicine, Chief medical informatics officer, Therapy, Patient, Fatty liver disease, WuXi Biologics, Pharmaceutical industry, Vaccine, Linking and intrusive R

CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced several milestones that support clinical advancement of its portfolio of novel antibodies: the nomination of two clinical candidates, key strategic collaborations with Pfizer Ignite and WuXi Biologics, and the appointment of Jeffrey D. Bornstein, M.D., as Chief Medical Officer.

Key Points: 
  • Mediar's first candidate, MTX-463, is a first-in-class monoclonal antibody designed to neutralize the WISP-1 signaling that is elevated in and contributes to fibrosis progression.
  • Its second candidate, MTX-474, is a first-in-class monoclonal antibody designed to neutralize the EphrinB2 signaling that causes fibrosis advancement and may play a role in defining the fibrotic niche.
  • Mediar plans to advance both MTX-463 and MTX-474 into Phase 1 clinical development in 2024.
  • In addition, he directed development programs, including those focused on fibrosis, at Biogen, Gilead Sciences, Elan Pharmaceuticals and other early-stage biotechnology companies.

Hippocratic AI Launches Physician Advisory Council; Nationally Recognized Providers to Help Shape First Safety-Focused LLM for Healthcare

Retrieved on: 
Tuesday, October 10, 2023
Senior, American Academy of Pediatrics, Hospital, The Council, United States Department of Health and Human Services, NYT, Pain, Safety, AAP, Health, Council, Medical director, Artificial intelligence, Patient, Entrepreneurship, Chief medical informatics officer, SVP, Mount Sinai Health System, Learning, LLM, Privacy, Secure access service edge, WebMD, Physician, Cleveland Clinic, PALO, Nursing, Medical device, Medscape, Hippocrates, Spine

PALO ALTO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the formation of its Physician Advisory Council to help shape its safety-focused Large Language Model (LLM) for healthcare.

Key Points: 
  • PALO ALTO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Hippocratic AI today announced the formation of its Physician Advisory Council to help shape its safety-focused Large Language Model (LLM) for healthcare.
  • Now, in helping shape the first safety-focused LLM for healthcare, they’re poised to empower the broader healthcare workforce, while simultaneously increasing patient access to high-quality care,” said Meenesh Bhimani MD, Co-Founder and Chief Medical Officer of Hippocratic AI.
  • The Physician Advisory Council further reflects Hippocratic AI’s commitment to building the safest and most medically accurate LLM possible.
  • “I’m thrilled to serve as an advisor to Hippocratic AI and play a role in guiding their LLM innovation.

Lark Health Expands Weight Management Program to Support Guided GLP-1 Care Delivery

Retrieved on: 
Thursday, September 28, 2023
Obesity, Education, Sleep, Centers for Disease Control and Prevention, Quality of life, Medicine, Annals of Behavioral Medicine, DPP, Genolier Swiss Medical Network SA, Research, Practice, Certification, Lark, CDC, Digital technology, Amwell, Patient, Lark Health, Healthy Weight Commitment Foundation, Chief medical informatics officer, Entrepreneurship, Behavioral medicine, Ecosystem, Independent Healthcare Providers Network, Pharmaceutical industry, Medical device

MOUNTAIN VIEW, Calif., Sept. 28, 2023 /PRNewswire/ -- Lark Health, the leading conversational-AI health coaching platform for the prevention and management of chronic conditions serving more than 2 million patients, announced today the expansion of its personalized weight management solutions to include an enhanced set of services designed to support employers and health plans through the unprecedented employee demand for GLP-1 medications.

Key Points: 
  • As part of this approach, Lark will now offer three new programs – the Healthy Weight program, GLP-1 Companion program, and Clinician-Guided Step Therapy program – all of which leverage the sustained behavior change, lifestyle management, and remote patient monitoring Lark is known for.
  • GLP-1 Companion Program is our comprehensive support program for those taking GLP-1 medications.
  • In addition to coaching on lifestyle modification, the program includes side effect management, medication adherence support, and clinical escalations as necessary.
  • Clinician-Guided Step Therapy is our program to provide access to end-to-end clinician-led therapy, offering insurance navigation, prescription management, lab monitoring, and ongoing management to ensure continuity of care.

SunCloud Health Opens Outpatient Mental Health Center in Gaithersburg

Retrieved on: 
Thursday, September 14, 2023
Yoga, IOP, DSM-IV codes, Health, Social, PHP, MD, Patient, Eating, Chief medical informatics officer, Adolescence, Biology, Addiction, Trauma, Nursing, Hospital, DMV

GAITHERSBURG, Md., Sept. 14, 2023 /PRNewswire/ -- SunCloud Health, a national leader in comprehensive mental health care for individuals with co-occurring disorders, has recently opened an outpatient center in Gaithersburg and is accepting new patients.

Key Points: 
  • GAITHERSBURG, Md., Sept. 14, 2023 /PRNewswire/ -- SunCloud Health, a national leader in comprehensive mental health care for individuals with co-occurring disorders, has recently opened an outpatient center in Gaithersburg and is accepting new patients.
  • The recently opened center offers a range of services, including a partial hospitalization program (PHP), an intensive outpatient program (IOP), and outpatient therapy.
  • The center serves adults of all genders with co-occurring mood disorders, eating disorders, addiction, and trauma.
  • The Gaithersburg center provides PHP with 6 hours of programming, 5 days a week, and IOP with 3.5 hours of programming, 5 days a week.

OneOncology and Its Practice Partners Celebrate Five Years of Cancer Care Excellence

Retrieved on: 
Wednesday, September 13, 2023
Partnership, Radiation, Pharmacy, Workflow, Disease, Cancer, Nuclear medicine, Genetic counseling, MD, Patient, Physician, Medicine, Palliative care, Chief medical informatics officer, Neoplasm, FDA, Safety, Nursing, Pharmaceutical industry

60 to 320 cancer care sites across all practice partners.

Key Points: 
  • 60 to 320 cancer care sites across all practice partners.
  • "As we've grown and enhanced world-class cancer care in communities across the country, strengthening practice independence and empowering their decision-making has always been our north star.
  • Since OneOncology was founded, OneOncology has:
    Enabled its practice partners to enroll more than 800 patients in interventional and observational clinical trials.
  • "OneOncology has accomplished a lot for its practice partners in five years," Dr. Patton said.

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

Retrieved on: 
Thursday, September 7, 2023
IRS, TMB, PD, ANN, Microsatellite instability, Stratum, Drug, Lung cancer, Biomarker, TPS, IHC, Medicare, Patient, Pathology, MSI, Cancer, Chief medical informatics officer, Pembrolizumab, PD-L1, Conference, Medical imaging, Pharmaceutical industry, NSCLC

ANN ARBOR, Mich., Sept. 7, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).

Key Points: 
  • ANN ARBOR, Mich., Sept. 7, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).
  • Strata Oncology announces data supporting utility of IRS score to guide first-line treatment decisions in NSCLC.
  • IRS can potentially guide treatment selection in this important and frequent clinical scenario," said Kat Kwiatkowski, Ph.D., Strata Oncology SVP, Clinical Development.
  • Immunotherapy Response Score is available clinically as part of the Strata SelectTM test, which is covered for Medicare beneficiaries with advanced solid tumors seeking additional treatment.

enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

Retrieved on: 
Thursday, September 7, 2023
Puma Biotechnology, Bachelor, Royal college, Biotechnology, University, Therapy, RCOG, Engen Botswana Limited, Bachelor of Medicine, Bachelor of Surgery, Membership of the Royal College of Physicians of Ireland, MRCGP, RCP, Carfilzomib, DDX, Royal Navy, Onyx Pharmaceuticals, EMA, LEGEND, Science, Patient, Liposarcoma, Chief medical informatics officer, Commander of the Navy (Sri Lanka), Growth, FDA, Puma, Pharmaceutical industry, EU, NMIBC, Medicine

"We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.

Key Points: 
  • "We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.
  • Before joining enGene, Dr. Bryce was most recently Chief Medical Officer at Rain Oncology, a late-stage company developing precision oncology therapeutics, where he built a clinical development team and oversaw multiple clinical studies, including a global Phase 3 registrational study in dedifferentiated liposarcoma.
  • Prior to that, he was Chief Medical & Scientific Officer at Puma Biotechnology, where he led the development strategy for neratinib.
  • He also served as a Surgeon Lieutenant Commander in the Royal Navy.

Rejuvenation Technologies Raises $10.6M Seed Financing Led by Khosla Ventures to Develop mRNA Therapeutics to Reverse Aging

Retrieved on: 
Wednesday, September 6, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Nobel Prize, DNA, Human, Partnership, Cell death, Telomerase, Telomere, Stanford University, Ageing, Multimedia, COVID, Cell, RNA, The FASEB Journal, Messenger, Lung, Pulmonary fibrosis, Cellular senescence, Notifiable disease, University, Khosla Ventures, Y Combinator, Immune system, Chief medical informatics officer, Mouse, Liver, LNP, University of Queensland, Cirrhosis, Company of Merchant Adventurers of London, B cell, Liver failure, IND, Rejuvenation, Pharmaceutical industry, Vaccine

Rejuvenation Technologies , a biotechnology company developing mRNA-based therapeutics to address mechanisms of aging, today announced a $10.6M seed financing round led by Khosla Ventures.

Key Points: 
  • Rejuvenation Technologies , a biotechnology company developing mRNA-based therapeutics to address mechanisms of aging, today announced a $10.6M seed financing round led by Khosla Ventures.
  • Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevity Tech Fund, and Y Combinator also participated in the round.
  • View the full release here: https://www.businesswire.com/news/home/20230906481334/en/
    From left to right, Rejuvenation Technologies Founders Glenn Markov, COO, John Ramunas, CEO.
  • We are excited to continue working together as Rejuvenation advances its technology platform, partnership discussions, and internal pipeline towards clinical trials.”